Qiagen, the new giant in next-gen sequencing tools?

17/01/2015 - 2 minutes

Yet again, a new acquisition in this beginning of 2015. Enzymatics, the Boston-area based Biotech company and leading provider of enzymes for Next-gen sequencing, has been acquired by Qiagen for a non-disclosed amount. The amount must be pretty high since Enzymatics’ enzymes are used in 80% of all NGS reactions and the company counts over 150 employees.

Enzymatic is the 3rd Boston-based company, featured in LaBiotech Tour Boston, and just brought major news on the table this week (after Moderna and Foundation Medicine). I visited the company, which is based in Beverly 30-minutes north of Boston by train. I discovered a great company, co-founded by the genetics rock-star George Church (also in the documentary here) who also contributed massively to the price decrease in NGS. I let Ian Ratcliffe, former CEO and Board Chairman present you the company:

The addition of this Enzymatics franchise adds a deep portfolio of capabilities to QIAGEN‘s strategy to offer a complete NGS workflow from biological samples to valuable molecular insights as well as to strengthen its broad and rapidly growing portfolio of “universal”

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member